Description
FibroMax: A complex of calculated indices for assessing the degree of fibrosis, steatosis, and the activity of the pathological process in the liver. FibroMax is a method for non-invasive (without biopsy) assessment of the condition of liver tissue. FibroMax consists of several laboratory tests, the results of which are used to calculate five critical indicators of liver tissue condition:
- fibrosis stage according to the METAVIR scale (FibroTest)
- degree of necroinflammatory reaction (ActiTest)
- degree of liver steatosis (fatty degeneration) (SteatoTest)
- diagnosis of non-alcoholic liver injury with determination of its activity - non-alcoholic steatohepatitis (NashTest)
- diagnosis of alcoholic liver injury with determination of its activity (AshTest)
The calculation algorithm was developed in France and validated in more than 40 independent international studies involving thousands of patients. The method is approved by the healthcare systems of France, the USA, Canada, the UK, and other countries. The efficacy of FibroMax as an alternative to liver biopsy has been proven in the vast majority of clinical situations. It allows for a comprehensive assessment of changes caused by liver disease. The test has high sensitivity and specificity regarding liver fibrosis and steatosis caused by viral or toxic factors, as well as diseases leading to liver tissue damage (diabetes mellitus, hyperlipidemia, excess body weight).
Indications for prescription:
- chronic hepatitis B
- chronic hepatitis C
- steatosis
- alcoholic steatohepatitis
- excess weight
- diabetes mellitus
- hypertensive disease
- hypercholesterolemia and hypertriglyceridemia
The analysis has some limitations (therefore, it is recommended to consult a doctor before undergoing the examination):
1. The test is not performed on patients under 18 years of age or patients with a transplanted liver.
2. The results of the study may be influenced by the following factors (the study has limited application or is not used in their presence):
- presence of acute hepatitis caused by hepatitis A, B, or Epstein-Barr virus
- presence of acute autoimmune hepatitis or drug-induced hepatitis
- Gilbert's syndrome with high hyperbilirubinemia
- intake of protease inhibitors (Indinavir, Atazanavir, Ritonavir)
- intake of azathioprine and ribavirin
- presence of chronic hemolysis (e.g., in patients with a prosthetic heart valve)
- cholelithiasis with acute cholestasis
- hepatonecrosis
- presence of acute infectious disease of the respiratory system or kidneys
- presence of lipemia and/or hemolysis in the obtained serum (the test is not performed)
3. The study results should be interpreted with caution if there is an isolated increase/decrease in one of the laboratory parameters (not correlating with the clinical situation), specifically:
- haptoglobin below 0.12 g/L or above 3.2 g/L
- transaminases above 622 IU/L
- bilirubin above 30 µmol/L
- GGT below 50 IU/L
- alpha-2 macroglobulin above 5.0 g/L
This test does not include a doctor's conclusion.
Period of execution
Within 6 days. The specified time does not include the day of biomaterial collection
Biomaterial type